参考文献/References:
[1].Arts T,Lyon A,Delhaas T,et al. Translating myosin-binding protein C and titin abnormalities to whole-heart function using a novel calcium-contraction coupling model[J]. J Mol Cell Cardiol,2024,190:13-23.
[2].Yogeswaran A,Troidl C,Mcnamara JW,et al. The C0-C1f region of cardiac myosin binding protein-C induces pro-inflammatory responses in fibroblasts via TLR4 signaling[J]. Cells,2021,10(6):1326.
[3].Heling L,Geeves MA,Kad NM. MyBP-C:one protein to govern them all[J]. J Muscle Res Cell Motil,2020,41(1):91-101.
[4].Risi CM,Belknap B,Atherton J,et al. Troponin structural dynamics in the native cardiac thin filament revealed by cryo electron microscopy[J]. J Mol Biol,2024,436(6):168498.
[5].Perazza LR,Wei G,Thompson LV. Fast and slow skeletal myosin binding protein-C and aging[J]. Geroscience,2023,45(2):915-929.
[6].Mamidi R,Gresham KS,Li J,et al. Cardiac myosin binding protein-C Ser(302) phosphorylation regulates cardiac β-adrenergic reserve[J]. Sci Adv,2017,3(3):e1602445.
[7].Hessel AL,Engels NM,Kuehn M,et al. Myosin-binding protein C forms C-links and stabilizes OFF states of myosin[J]. bioRxiv[Preprint],2023 Sep 12:2023.09.10.556972. DOI:10.1101/2023.09.10.556972.
[8].Donaldson C,Palmer BM,Zile M,et al. Myosin cross-bridge dynamics in patients with hypertension and concentric left ventricular remodeling[J]. Circ Heart Fail,2012,5(6):803-811.
[9].Cizauskas HE,Burnham HV,Panni A,et al. Proteolytic degradation of atrial sarcomere proteins underlies contractile defects in atrial fibrillation[J]. bioRxiv[Preprint],2023 Nov 5:2023.11.05.565691. DOI:10.1101/2023.11.05.565691..
[10].Suay-Corredera C,Alegre-Cebollada J . The mechanics of the heart:zooming in on hypertrophic cardiomyopathy and cMyBP-C[J]. Febs Lett,2022,596(6):703-746.
[11].Dutta D,Nguyen V,Campbell KS,et al. Cryo-EM structure of the human cardiac myosin filament[J]. Nature,2023,623(7988):853-862.
[12].Hanft LM,Fitzsimons DP,Hacker TA,et al. Cardiac MyBP-C phosphorylation regulates the Frank-Starling relationship in murine hearts[J]. J Gen Physiol,2021,153(7):e202012770.
[13].Liang C,Aisa Z,Sun L,et al. Cardiac ischemic preconditioning promotes cMyBP-C phosphorylation by inhibiting the calpain-mediated proteolysis[J]. Exp Cell Res,2023,433(2):113859.
[14].Kochurova AM,Beldiia EA,Nefedova VV,et al. N-terminal fragment of cardiac myosin binding protein c modulates cooperative mechanisms of thin filament activation in atria and ventricles[J]. Biochemistry (Mosc),2024,89(1):116-129.
[15].Wong FL,Bunch TA,Lepak VC,et al. Cardiac myosin-binding protein C N-terminal interactions with myosin and actin filaments:opposite effects of phosphorylation and M-domain mutations[J]. J Mol Cell Cardiol,2024,186:125-137.
[16].Tanner BCW,Awinda PO,Agonias KB,et al. Sarcomere length affects Ca2+ sensitivity of contraction in ischemic but not non-ischemic myocardium [J]. J Gen Physiol,2023,155(3):e202213200.
[17].Nelson S,Beck-Previs S,Sadayappan S,et al. Myosin-binding protein C stabilizes,but is not the sole determinant of SRX myosin in cardiac muscle[J]. J Gen Physiol,2023,155(4):e202213276.
[18].Tanner BCW,Previs MJ,Wang Y,et al. Cardiac myosin binding protein-C phosphorylation accelerates β-cardiac myosin detachment rate in mouse myocardium[J]. Am J Physiol Heart Circ Physiol,2021,320(5):H1822-H1835.
[19].Van-Dijk SJ,Kooiker KB,Napierski NC,et al. Point mutations in the tri-helix bundle of the M-domain of cardiac myosin binding protein-C influence systolic duration and delay cardiac relaxation[J]. J Mol Cell Cardiol,2018,119:116-124.
[20].Barefield DY,Mcnamara JW,Lynch TL,et al. Ablation of the calpain-targeted site in cardiac myosin binding protein-C is cardioprotective during ischemia-reperfusion injury[J]. J Mol Cell Cardiol,2019,129:236-246.
[21].Razzaque MA,Gupta M,Osinska H,et al. An endogenously produced fragment of cardiac myosin-binding protein C is pathogenic and can lead to heart failure[J]. Circ Res,2013,113(5):553-561.
[22].Rosas PC,Warren CM,Creed HA,et al. Cardiac myosin binding protein-c phosphorylation mitigates age-related cardiac dysfunction:hope for better aging?[J]. JACC Basic Transl Sci,2019,4(7):817-830.
[23].Sevrieva IR,Ponnam S,Yan Z,et al. Phosphorylation-dependent interactions of myosin-binding protein C and troponin coordinate the myofilament response to protein kinase A[J]. J Biol Chem,2023,299(1):102767.
[24].Mamidi R,Gresham KS,Stelzer JE. Length-dependent changes in contractile dynamics are blunted due to cardiac myosin binding protein-C ablation[J]. Front Physiol,2014,5:461.
[25].Kampourakis T,Ponnam S,Campbell KS,et al. Cardiac myosin binding protein-C phosphorylation as a function of multiple protein kinase and phosphatase activities[J]. Nat Commun,2024,15(1):5111.
[26].Copeland O,Sadayappan S,Messer AE,et al. Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle[J]. J Mol Cell Cardiol,2010,49(6):1003-1011.
[27].Sadayappan S,Gulick J,Osinska H,et al. Cardiac myosin-binding protein-C phosphorylation and cardiac function[J]. Circ Res,2005,97(11):1156-1163.
[28].Lynch TL,Sadayappan S. Surviving the infarct:A profile of cardiac myosin binding protein-C pathogenicity,diagnostic utility,and proteomics in the ischemic myocardium[J]. Proteomics Clin Appl,2014,8(7-8):569-577.
[29].Govindan S,Sarkey J,Ji X,et al. Pathogenic properties of the N-terminal region of cardiac myosin binding protein-C in vitro[J]. J Muscle Res Cell Motil,2012,33(1):17-30.
[30].Rosas PC,Solaro RJ. Implications of S-glutathionylation of sarcomere proteins in cardiac disorders,therapies,and diagnosis[J]. Front Cardiovasc Med,2022,9:1060716.
[31].Rosas PC,Liu Y,Abdalla MI,et al. Phosphorylation of cardiac myosin-binding protein-C is a critical mediator of diastolic function[J]. Circ Heart Fail,2015,8(3):582-594.
[32].Gupta MK,Gulick J,James J,et al. Functional dissection of myosin binding protein C phosphorylation[J]. J Mol Cell Cardiol,2013,64:39-50.
[33].Lovelock JD,Monasky MM,Jeong EM,et al. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity[J]. Circ Res,2012,110(6):841-850.
[34].Teerlink JR,Diaz R,Felker GM,et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure[J]. N Engl J Med,2021,384(2):105-116.
[35].Ismayl M,Abbasi MA,Marar R,et al. Mavacamten treatment for hypertrophic cardiomyopathy:a systematic review and meta-analysis of randomized controlled trials[J]. Curr Probl Cardiol,2023,48(1):101429.
[36].Bunch TA,Guhathakurta P,Thompson AR,et al. Drug discovery for heart failure targeting myosin-binding protein C[J]. J Biol Chem,2023,299(12):105369.
[37].Da’as SI,Hasan W,Salem R,et al. Transcriptome profile identifies actin as an essential regulator of cardiac myosin binding protein C3 hypertrophic cardiomyopathy in a zebrafish model[J]. Int J Mol Sci,2022,23(16):8840.
[38].Li J,Mamidi R,Doh CY,et al. AAV9 gene transfer of cMyBPC N-terminal domains ameliorates cardiomyopathy in cMyBPC-deficient mice[J]. JCI Insight,2020,5(17):e130182.
相似文献/References:
[1]戴玫,付珞,胡建英,等.慢性心力衰竭患者应用高强度间歇性有氧训练研究进展[J].心血管病学进展,2016,(3):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
DAI Mei,FU Luo,HU Jianying,et al.Advances in Research on High-intensity Interval Training in Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2016,(12):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
[2]张培,综述,刘剑,等.慢性心力衰竭并发肌少症的研究进展[J].心血管病学进展,2016,(3):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
ZHANG Pei,LIU Jian.Research Progress in Chronic Heart Failure-induced Sarcopenia[J].Advances in Cardiovascular Diseases,2016,(12):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
[3]田晶,张青,张岩波,等.慢性心力衰竭结局评价指标研究进展[J].心血管病学进展,2019,(6):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
TIAN Jing,ZHANG qing,ZHANG Yanbo,et al.Outcome Indicators for Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
[4]胡威,苏芳菊,张卫泽.左室四极导线在心脏再同步化治疗中的应用进展[J].心血管病学进展,2020,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
HU Wei,SU Fangju,ZHANG Weize.Application of Left Ventricular Quadrupole in Cardiac Resynchronization Therapy[J].Advances in Cardiovascular Diseases,2020,(12):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
[5]郭岐龙 芦颜美 张玲 张疆华 邢强 祖克拉·吐尔洪 李耀东 周贤惠 汤宝鹏.新疆地区老年慢性心力衰竭住院患者的病因、合并症及药物治疗的多中心回顾性分析[J].心血管病学进展,2020,(4):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
GUO Qilong,LU Yanmei,ZHANG Ling,et al.Etiology, Comorbidity and Drug Treatment of Elderly Inpatients with Chronic Heart Failure in Xinjiang: A Multi-center Retrospective Study[J].Advances in Cardiovascular Diseases,2020,(12):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
[6]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(12):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[7]郭曦滢,孙煌,樊朝美,等.非奈利酮治疗慢性心力衰竭的研究进展[J].心血管病学进展,2020,(10):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
GUO XiyingSUN HuangFAN ChaomeiZHANG Jian.Finerenone in the Treatment of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(12):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
[8]吴燕婷 李萍 吴寒.慢性心力衰竭再住院率研究进展[J].心血管病学进展,2021,(8):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
WU Yanting,LI Ping,WU Han.Rehospitalization Rate of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2021,(12):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
[9]陈晓梅 陈巧玮 曾纪娟 张庆.可穿戴设备在慢性心力衰竭患者管理中的应用进展[J].心血管病学进展,2023,(3):233.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.010]
CHEN Xiaomei,CHEN Qiaowei,ZENG Jijuan,et al.Application of Wearable Devices in Management of Patients with Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2023,(12):233.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.010]
[10]李彤 呼海娟 崔炜.慢性心力衰竭患者脑钠肽抵抗机制的研究进展[J].心血管病学进展,2023,(3):238.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.011]
LI Tong,HU Haijuan,CUI Wei.Mechanism of Brain Natriuretic Peptide Tolerance in Patients with Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2023,(12):238.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.011]